Organization (Industry)
Innoviva, Inc.
ClinicalTrials.gov lists Innoviva, Inc. as lead sponsor of 29 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
21 sections measured, none recorded
This page covers Innoviva, Inc. and 3 companies grouped under it: 29 lead-sponsored trials (0 its own, 29 in the grouped companies) and 4 legal-entity registrations (2 its own, 2 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| La Jolla Pharmaceutical (United States) | 18 | 1 |
| Entasis Therapeutics (United States) | 9 | 1 |
| Innoviva Specialty Therapeutics | 2 | 0 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 400 | 0 | 2014-06-17 |
Latest dated events (400)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2014-06-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2014-06-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2014-05-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2014-05-20 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2014-05-06 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 400 events.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, disease areas, trials by start year as sponsor or collaborator, active development programs, approved assets, sponsor delivery record, journals published in, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.